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In their white paper, Holmes, Jr. et al. (1) do not refer to hyper-
sensitivity coronary syndrome.
However, I strongly believe that stent thrombosis (ST) is
principally a manifestation of Kounis hypersensitivity coronary
syndrome (2), caused by an “antigenic complex” of nickel alloys,
polymers, eluted drugs, and possibly concomitant oral antiplate-
let drugs and environmental exposures. Thus far, all clinical
reports and reported pathologic findings in all patients who
have died of ST, and all animal studies and experiments, point
toward hypersensitivity inflammation with infiltration of vari-
ous interrelated and interacting inflammatory cells, including
eosinophils, macrophages, T cells, and mast cells. Following are
some examples (3–5):
• In patients who developed ST associated with generalized
allergic reactions, induced by environmental causes, stents act
like magnets attracting inflammatory cells and constitute the
area of possible intracoronary mast cell and platelet activation
in order to develop ST.
• In the Research on Adverse Drug Events and Reports
project, definite ST cases showed peripheral eosinophilia and
raised immunoglobulin E titers over 5 times normal, together
with eosinophilic thrombus infiltration.
• In serum sickness–like reactions after sirolimus-eluting
stent implantation, symptoms did not resolve after the
discontinuation of clopidogrel and substitution with ticlo-
pidine, but they resolved with prednisone. However,
prednisone abolished symptoms despite aspirin and clopi-
dogrel continuation.
• In occluded biliary stents, pathology revealed infiltration of
eosinophils and lymphocytes compatible with nickel allergic
reaction.
• In thrombus sections stained with hematoxylin and eosin,
neutrophils and eosinophils were associated with stent appo-
sition, suggesting an allergic hypersensitivity reaction.
• In sirolimus-eluting stents, localized coronary hypersensitiv-
ity vasculitis and acute myocardial infarction were induced
from late ST.
• In patients who received stents and died of multivessel spasm,
histologic findings revealed inflammatory cells in the intima
and adventitia. Giemsa staining showed few scattered mast
cells.
I wonder how many of us have noticed that manufacturers’
information sheets accompanying the new generation of stents
state clearly that they are contraindicated for use in patients with
hypersensitivity to any stent component.
In conclusion, antigen-free stents should be implanted to avoid
catastrophic ST.*Nicholas G. Kounis, MD, PhD
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Stent Thrombosis
Did Biodegradable Polymers
Fail or Are We Too Impatient?
We read with interest the report by Holmes et al. (1), in which the
current knowledge about stent thrombosis is revisited, and the
possibility that biodegradable polymers improve the long-term
safety of drug-eluting stents is mentioned. Durable polymers are
associated with persistent arterial wall inflammation and delayed
vascular healing, both related to stent thrombosis (2). New
biodegradable polymers completely degrade in 6 to 9 months,
leaving behind only the bare-metal stent structure.
Apart from the LEADERS (Limus Eluted From a Durable
Versus Erodable Stent Coating) trial (3), many trials have com-
pared biodegradable with durable polymers. We have performed a
meta-analysis of 7 randomized trials comparing durable with
biodegradable polymers (COSTAR-II [Cobalt Chromium Stent
With Antiproliferative for Restenosis II], ISAR-TEST-3 [Intra-
coronary Stenting and Angiographic Results: Test Efficacy of
Rapamycin-Eluting Stents With Different Polymer Coating Strat-
egies], ISAR-TEST-4 [Intracoronary Stenting and Angiographic
Results: Test Efficacy of 3 Limus-Eluting Stents], LEADERS,
NOBORI-CORE [A Prospective, Non-Randomized, Multi-
Center Comparative Study of Nobori Drug Eluting Stent Systems
Versus Cypher Drug Eluting Stent System], NOBORI-I [A
Prospective, Randomized, Multi-Centre Comparison of Nobori
and Taxus Drug Eluting Stent Systems], and NEVO
